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OBJECTIVES We sought to evaluate the impact of percutaneous transluminal coronary angioplasty (PTCA)
and medical treatment on self-perceived quality of life among patients with angina.
BACKGROUND The second Randomized Intervention Treatment of Angina trial (RITA-2) implemented
initial policies of PTCA or continued medical treatment in patients with angina, allowing
assessment of long-term health consequences.
METHODS A total of 1,018 patients were randomly assigned (504 to PTCA and 514 to medical
treatment). The short form 36 (SF-36) self-administered quality-of-life questionnaire was
completed at randomization and three months, one year and three years later. To date, 98%
of patients reached one year and 67% reached three years.
RESULTS The PTCA group had significantly greater improvements in physical functioning, vitality and
general health at both three months and one year, but not at three years. These quality-of-life
scores were strongly related to breathlessness, angina grade and treadmill exercise time both
at baseline and at one year. The treatment differences in quality of life are explained by the
PTCA group’s improvements in breathlessness, angina and exercise time. The attenuation of
treatment difference at three years is partly attributed to 27% of medically treated patients
receiving nonrandomized interventions in the interim. For both groups, there were also
improvements in ratings of physical role functioning, emotional role functioning, social
functioning, pain and mental health, but for these the superiority of PTCA over medical
treatment was less pronounced. After one year, 33% and 22% of the PTCA and medical
groups, respectively, rated their health much better.
CONCLUSIONS Coronary angioplasty substantially improves patient-perceived quality of life, especially
physical functioning and vitality, as compared with continued medical treatment. These
differences are attributed to alleviation of cardiac symptoms (specifically, breathlessness and
angina), but must be balanced against the small procedure-related risks of PTCA. (J Am Coll
Cardiol 2000;35:907–14) © 2000 by the American College of Cardiology
Percutaneous transluminal coronary angioplasty (PTCA) is
a commonly used intervention for relief of angina in patients
with coronary artery disease (CAD). However, there is little
previous evidence from randomized trials to assess its effect
on cardiac symptoms and other aspects of health, as com-
pared with a policy of continued use of antianginal medi-
cations.
The second Randomized Intervention Treatment of An-
gina trial (RITA-2) compared the long-term effects of
initial treatment strategies of PTCA and continued medical
treatment in patients with CAD. Interim results (1) over a
median follow-up of 2.7 years indicated a marked superior-
ity of PTCA with respect to prevalence of angina and
exercise test performance, especially in patients with more
severe angina at baseline. However, such benefit needs to be
balanced against the small increased hazard of procedure-
related myocardial infarction (MI). Specifically, seven pa-
tients (1.4%) had a procedure-related definite MI, and
overall the PTCA group had a 3.0% excess of definite MI or
death, the primary end point (95% confidence interval 0.4%
to 5.7%).
The aim of this report is to describe the impact of these
two treatment strategies on health-related quality of life
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(perceived health status) over three years since randomiza-
tion using the SF-36 self-administered questionnaire.
METHODS
The RITA-2 trial design has been described previously in
detail (1). Briefly, patients with arteriographically proven
CAD were eligible if they had a significant stenosis in at
least one major epicardial vessel and their supervising
cardiologist thought that both continued medical therapy
and PTCA were acceptable alternatives. Eligible patients
who provided written, informed consent to participate were
randomized to one of these policies by telephone.
Patients randomly assigned to PTCA were scheduled to
undergo an intervention within three months, and this was
achieved in 93%. The intended strategy was based on
conventional balloon dilation, but stents were permissible if
the initial angioplasty result was unsatisfactory.
Patients assigned to medical treatment were prescribed
antianginal medication for symptom relief, with a later
myocardial revascularization procedure reserved for patients
whose symptoms were not adequately controlled by optimal
medical therapy. This usually included a beta-adrenergic
blocker, a calcium antagonist or a long-acting nitrate in
maximally tolerated doses, or a combination of these. All
patients in both groups were treated with aspirin unless
contraindicated.
Patients were assessed at baseline and at three months, six
months and yearly after randomization. Angina was as-
sessed with the Canadian Cardiovascular Society’s classifi-
cation (2) and by documentation of antianginal drug use.
Breathlessness was assessed on a 6-point scale: not breath-
less, breathless climbing hills, hurrying on the level, walking
at own pace, dressing or washing, and breathless at rest.
Exercise treadmill testing was done according to the Bruce
protocol (3). All deaths, MIs and coronary intervention
procedures were documented on event-specific forms.
Patients assessed their quality of life using the SF-36
health survey (4,5) at baseline, three months, one year and
three years. The SF-36 comprises 36 items that can be
combined into the following eight multi-item summary
scores: physical functioning (10 items), vitality (four items),
bodily pain (two items), mental health (five items), social
functioning (two items), role limitation due to physical
health (four items) and due to emotional problems (three
items) and general health perceptions (five items), plus one
item assessing a change in health over the past year. Each
summary score is obtained by simple unweighted summa-
tion of item scores and is then scaled from 0 to 100, with 0
and 100 indicating “worst” and “best” possible health,
respectively (higher scores indicate better perceived health).
The SF-36 has been validated for use in a British setting (6).
A total of 1,018 patients in 20 cardiology centers in the
United Kingdom and Ireland were randomized (504 to
PTCA and 514 to medical therapy) from July 1992 to May
1996. This report relates to all follow-up data available as of
December 31, 1997. Accordingly, 98% of patients still alive
achieved one-year follow-up and 67% reached their three-
year follow-up visit.
Treatment comparisons for each quality-of-life measure
at each time point were based on mean differences, adjusted
for baseline score using analysis of covariance. Standard
methods of multiple regression were used to assess the
simultaneous influence of treatment and other patient fac-
tors on quality-of-life scores. All data were analyzed accord-
ing to the original treatment assignment (intention to treat).
RESULTS
For the eight aspects of health-related quality of life
measured by the SF-36, Figure 1 shows the mean 6 SEM
scores by treatment group at randomization (baseline) and
at three months, one year and three years of follow-up. Both
the PTCA and medical therapy groups showed substantial
improvements over the first year in most aspects of quality
of life, especially in physical role functioning, although the
medical therapy group showed no change in their rating of
general health.
The PTCA group showed highly significant superiority
over the medical group in terms of physical functioning,
vitality and general health at both three months and one
year after randomization. Mental health was also signifi-
cantly better in the PTCA group at three months and one
year, although the magnitude of this difference was quite
small. The slight superiority of the PTCA group in pain,
social functioning and physical and emotional role function-
ing did not achieve such marked levels of statistical signif-
icance. None of the eight SF-36 scores showed a significant
treatment difference at three years. All these treatment
comparisons were done using analysis of covariance, adjust-
ing for the patient’s baseline score.
Next, physical functioning, vitality and general health
were studied to determine their substantial treatment dif-
ferences and other patient characteristics affecting these
quality-of-life aspects. For physical functioning at one year,
9.7% of PTCA patients and 4.8% of medically treated
patients achieved the maximal score of 100 (i.e., no limita-
tion for all 10 items). A further 29.2% of PTCA patients
and 20.8% of medically treated patients scored $90, which
indicates either one item with “much limitation” or, at most,
two of the 10 items with “little limitation.” The distribu-
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
RITA-2 5 second Randomized Intervention Treatment
of Angina trial
SF-36 5 short form 36
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tions of physical functioning are otherwise skewed to the
left, with the PTCA and medical groups having similar rates
of poor physical functioning, with 15.6% and 17.4%, re-
spectively, scoring ,50.
Vitality at one year showed a more symmetric distribu-
tion, with an evident treatment difference in the extremes.
That is, a score of $80 occurred for 22.8% and 15.4% of
PTCA and medically treated patients, respectively, whereas
a score of ,20 occurred for 3.3% and 6.4%, respectively.
General health at one year showed a similar pattern: a high
rating $80 was given by 28.4% and 19.2% of PTCA and
medically treated patients, respectively, whereas a rating
,50 occurred for 26.1% and 35.9%, respectively.
Most of the 19 individual questions related to physical
functioning (n 5 10), vitality (n 5 4) and general health
(n 5 5) showed significant treatment differences in their
own right, demonstrating the broad range of physical and
general health issues that are improved by PTCA. The four
items exhibiting the most marked treatment difference were
a true or false grading of “my health is excellent,” as well as
limitations in vigorous activity, carrying groceries and
climbing more than one flight of stairs. The patients’
self-perception of their change in general health over the
past year revealed that 33.4% of PTCA patients felt much
better as compared with 21.5% of medically treated patients,
whereas 14.7% of the medically treated patients felt some-
what or much worse as compared with only 9.2% of the
PTCA patients.
The presence of anginal symptoms has a major influence
on many aspects of quality of life (7), and the previously
reported treatment difference in prevalence of angina (1) can
be linked to the quality-of-life differences cited earlier.
Figure 2 shows the mean quality-of-life scores at one year
(for physical functioning, vitality and general health), plot-
ted by angina grade at one year separately for the two
treatment groups. Each plot shows a steep deterioration in
quality-of-life score by worsening angina grade, which is
similar for both treatment groups. The medical therapy
group has fewer patients with no anginal symptoms (46.8%
of medical therapy group vs. 65.0% of PTCA group) and
substantially more patients above any particular angina
grade (e.g., 27.6% of medical therapy group vs. 17.0% of
PTCA group with angina grade 2 or worse, p , 0.001). The
similarity between the two plots for PTCA and medical
therapy implies that the treatment differences in quality-of-
life scores are largely attributable to their difference in the
prevalence and severity of angina.
Many patient characteristics could potentially be associ-
ated with quality-of-life scores, and we chose the following
to investigate: age, gender, previous MI, recent unstable
angina and number of diseased vessels (all recorded at
baseline) and angina, breathlessness, exercise treadmill time
and number of antianginal drugs (both at baseline and
during follow-up visits).
Physical functioning, vitality and general health scores, at
both baseline and at one year follow-up, all showed pro-
nounced trends with the current angina grade, breathless-
ness grade, number of antianginal drugs and treadmill
exercise time. Female patients had a significantly worse
rating of physical functioning and vitality. Physical func-
Figure 2. Mean 6 SEM scores for physical functioning, vitality and general health at one year, plotted by angina grade at one year,
separately for each treatment group.
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tioning declined with age, whereas self-perception of vitality
and general health increased slightly with age. Previous MI,
recent unstable angina and number of diseased vessels
showed no association with quality-of-life scores.
To simultaneously relate all of these patient determinants
of quality-of-life scores, multiple regression analyses were
done (Table 1). For physical functioning, vitality and general
health scores at baseline, the patient’s breathlessness grade was
the strongest independent predictor in each case. Angina
grade was also a highly significant predictor in each case,
although exercise time was an even stronger predictor of the
physical functioning score. The number of antianginal drugs
was more weakly related to quality-of-life scores. After
allowing for other predictors, female patients still had lower
scores for physical functioning and vitality, whereas increas-
ing age was significantly related to better quality-of-life
scores.
For the regression analyses of physical functioning, vital-
ity and general health scores at one year after randomization,
two additional predictors were included—treatment and
baseline score. In each case, the baseline score was the
strongest predictor of the one-year score, indicating an
underlying consistency over time in patient self-assessment
of quality of life. One-year measures of breathlessness,
angina grade and exercise time were all strongly predictive
of each of the three quality-of-life scores assessed at one
year, the pattern of relations being similar to that observed
at baseline. There was no gender difference, presumably
because baseline score differences were accounted for in the
model. Older patients still had significantly higher scores for
vitality and general health after allowing for the other
predictors. Treatment group was not a significant indepen-
dent predictor of quality of life at one year after allowing for
these other factors, which means that the observed superi-
ority of PTCA for quality of life at one year can be
attributed to the treatment differences in angina grade,
exercise time and breathlessness recorded at one year.
Subgroup analyses were performed to see whether any
specific types of patient had a particularly strong (or weak)
quality-of-life benefit from PTCA, but no such clear-cut
associations were identified. However, for both the PTCA
and medical therapy group, the quality-of-life scores at one
year were strongly linked to angina grade, breathlessness
and exercise time at baseline. To illustrate this point,
patients were categorized into seven ordered prognostic
groups (Table 2).
Table 1. Multiple Regression Analyses of Quality-of-Life Scores on Patient Characteristics
At Baseline (n 5 951)
Physical Functioning Vitality General Health
Coefficient t Coefficient t Coefficient t
Breathlessness grade 25.53 212.5 24.20 28.8 23.65 27.8
Angina grade 23.53 26.6 24.28 27.3 23.15 25.5
Exercise time (min) 2.11 9.2 0.58 2.3 1.23 5.0
No. of antianginal drugs 21.62 22.3 21.73 22.2 21.54 22.0
Gender (M 5 0, F 5 1) 27.99 25.3 25.72 23.5 3.32 2.1
Age (per 10 years) 1.57 2.3 4.26 5.8 4.24 5.9
At One Year (n 5 873)
Physical Functioning Vitality General Health
Coefficient t Coefficient t Coefficient t
Breathlessness grade* 23.87 27.9 22.80 25.6 22.10 24.0
Angina grade* 23.05 25.6 23.14 25.6 22.59 24.4
Exercise time (min)* 1.62 6.9 0.87 3.7 0.97 4.0
No. of antianginal drugs* 22.07 23.4 20.79 21.3 22.55 23.9
Gender (M 5 0, F 5 1) 21.11 20.8 20.31 20.2 0.80 0.5
Age (per 10 years) 0.32 0.5 2.13 3.4 1.38 2.1
Baseline score 0.35 13.4 0.47 17.9 0.55 19.4
Treatment
(medical treatment 5 0,
PTCA 5 1)
0.80 0.8 20.54 20.5 20.29 20.3
*As measured at one year. For each of these six multiple regression analyses, the coefficient for each variable indicates the
magnitude of its contribution to predicting quality of life (e.g., a one-grade increase in breathlessness at baseline independently
predicts a mean loss of 5.53 points for physical functioning at baseline if all of the other five variables remain unchanged). The
t value indicates the strength of evidence for the prediction, being the coefficient divided by its standard error (not given): that
is, u t u . 1.96, u t u . 2.58, u t u . 3.29, u t u . 3.89 means p , 0.05, p , 0.01, p , 0.001 and p , 0.0001, respectively.
Table 2. A Simple Scoring for Disease Severity at Baseline*
Score
Angina
Grade Breathlessness
Exercise Time
(min)
0 0 or 1 0 .9
1 2 1 or 2 6–9
2 3 or 4 3, 4 or 5 ,6
* (best score 5 0, worst score 5 6).
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By summing the three scores (each 0, 1 or 2), the
extremely good prognosis group (little or no angina, no
breathlessness and good exercise time) and the extremely
bad prognosis group (severe angina, severe breathlessness
and poor exercise time) scored 0 and 6, respectively. Inter-
mediate scores reflect an ordering of patient severity based
on these three simple gradings. Table 3 shows the conse-
quent mean quality-of-life scores at one year for these
prognostic groupings, which exhibit very consistent trends
in both treatment groups.
The superiority of PTCA with respect to physical func-
tioning, vitality and general health had attenuated substan-
tially by three years of follow-up (Fig. 1). This may be
partially explained by the “cross-over” of some medically
treated patients who received nonrandomized PTCA or
coronary artery bypass graft surgery (CABG), or both,
during the intervening period. Medically treated patients
subsequently receiving coronary interventions had lower
quality-of-life scores at baseline as compared with patients
who stayed on medication alone. Those receiving CABG
(n 5 28) had marked improvements in physical functioning,
vitality and general health at three years, whereas those
receiving PTCA only (n 5 62) showed little change, like
those staying on medical treatment (n 5 246). However,
interpretation of such nonrandomized comparisons is diffi-
cult. For instance, those receiving PTCA presumably had
worsening symptoms beforehand and some improvement
afterward.
DISCUSSION
Treatment differences in quality of life. We have previ-
ously reported (1) that a policy of immediate PTCA for
patients with angina leads to substantial improvements in
angina, breathlessness and exercise test performance as
compared with a policy of continued medical therapy, with
these differences being most marked in the first year. Here,
we have quantified how these differences translate into
patient self-perceptions of improved quality of life after
PTCA.
The SF-36 is a generic quality-of-life instrument not
created especially for angina studies. Nevertheless, in
RITA-2, it has ably documented patient self-perceived
benefits of PTCA, especially regarding physical functioning,
vitality and general health. In particular, a simple 5-point
grading of “my health is excellent,” from definitely false to
definitely true, demonstrated the superiority of PTCA after
one year. The physical functioning differences were espe-
cially marked: the 10 component items relate to functions
inhibited by anginal symptoms, such as limitations in
vigorous activity and climbing more than one flight of stairs.
Other scales of the SF-36 (physical and emotional role
functioning, social functioning, pain and mental health)
were less able to quantify significant treatment differences,
although all still tended to favor PTCA over continued
medical treatment. Some items (e.g., mental health) have a
less direct link to symptomatic CAD, whereas for others
(e.g., pain and physical and emotional role functioning), the
specific SF-36 questions appear too general to elicit specific
limitations of anginal chest pain. The questions on physical
and emotional role functioning may be less suited to people
retired or not employed (a sizable proportion of RITA-2
patients).
Influence of angina grade and breathlessness. Patient
self-ratings of physical functioning, general health and
vitality have a consistent close relation to angina grade (Fig.
2), both before randomized treatment and one year later.
The first RITA trial (7), which compared PTCA and
CABG in 1,011 patients with angina, used the Nottingham
Health Profile in demonstrating similarly strong links.
Clearly, the extra relief of anginal symptoms achieved by
PTCA (and CABG) is a prime reason for its patient-
perceived quality-of-life benefits. However, a more thor-
ough statistical investigation of the predictors of such
patient-perceived quality of life (Table 1) reveals a more
complex picture. Breathlessness appears to be the strongest
influence on physical functioning, vitality and general
health, both before randomized treatment and one year
later. Because PTCA also improves breathlessness (1), there
is more to the benefits of PTCA than simply relief of
anginal pain, and more understanding of the causes and
consequences of breathlessness in patients with CAD is
required.
Table 3. Mean Quality-of-Life Scores at One Year by Treatment Group and by Disease Severity at Baseline*
Disease
Severity
PTCA Group Medical Treatment Group
n
Physical
Functioning Vitality
General
Health n
Physical
Functioning Vitality
General
Health
0 (mild) 59 89.0 71.8 75.6 72 86.6 65.1 70.4
1 88 82.5 63.2 66.4 83 78.2 60.1 65.8
2 98 79.2 58.6 66.1 102 73.1 59.0 59.2
3 92 71.7 56.4 58.6 92 68.5 54.8 55.5
4 62 66.7 51.8 56.6 65 59.5 46.4 54.0
5 34 61.1 50.7 58.2 37 52.9 40.7 45.8
6 (severe) 21 52.2 41.4 49.0 23 48.3 45.7 45.7
*Scored from 0 to 6 based on baseline angina grade, breathlessness and exercise time.
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Other quality-of-life predictors. Exercise test perfor-
mance is also a highly significant independent predictor of
patient-perceived quality of life, especially physical func-
tioning. Hence, poor exercise time is a measurement of
some meaningful impairment of a patient’s quality of life,
which is not wholly represented by gradings of symptoms.
Women tend to have notably lower self-perceptions of
physical functioning and vitality as compared with men, and
although this may not be wholly specific to patients with
angina, such gender differences were much smaller in a
general population (8). The higher ratings of vitality and
general health in older patients may reflect a greater toler-
ance of reduced health status as people age; however, there
are currently no SF-36 elderly general population norms.
The quality-of-life benefits of PTCA are not confined to
any particular subgroup of patients. For instance, patients
ranked into prognostic groups based on their angina grade,
breathlessness and exercise time at baseline showed a strong
relation with quality of life one year later. However, for the
whole spectrum of patients with angina, there was a
consistently superior quality of life in patients who had
PTCA as compared with medical treatment.
Attenuation of effect over time? The durability of the
quality-of-life benefits of PTCA is of interest. Figure 1
suggests that the benefits have largely disappeared after
three years, but RITA-2 is a pragmatic trial of two strate-
gies: immediate PTCA (plus any subsequent interventions
thought to be clinically appropriate) versus continued med-
ical treatment (with later myocardial revascularization pro-
cedures if symptoms are not adequately controlled). Thus,
this policy-oriented comparison between immediate PTCA
and later PTCA (or CABG), as necessary, cannot directly
answer the question of how long the benefits of PTCA last.
Ten percent of PTCA patients received CABG within
three years. Also, 27% of medically treated patients had
PTCA or CABG, or both, within three years. These
patients tended to be sicker initially and subsequently
benefited from the effects of revascularization. Hence, the
treatment difference is inevitably diluted at three years,
because the policies become less distinguishable as time goes
by. Therefore, it would be wrong to infer that the quality-
of-life benefits of PTCA do not last three years.
Previous studies. Although quality-of-life assessment gen-
erates much debate, there are relatively few major clinical
trials reporting results of validated quality-of-life instru-
ments, such as the SF-36. For instance, in angina pectoris
the use of these instruments seems mostly confined to
smaller trials without clinically relevant treatment differ-
ences (9,10) and to nonrandomized, uncontrolled before-
and-after studies (11–14), without recognizing that quality-
of-life changes might well have occurred even without a
therapeutic intervention. Moreover, studies of quality of life
need to be sufficiently large to reliably estimate effects (15).
The relevant Angioplasty Compared to Medical Therapy
(ACME) study (16) of 212 patients with single-vessel disease
randomized to PTCA or medical therapy found greater im-
provements at six months in both physical functioning and
psychological well-being for patients receiving PTCA, but only
in patients with increased exercise performance.
Importance of control groups. In RITA-2, the apparent
benefits of PTCA would have looked greater if we had ignored
the improvements also occurring in the control group (Fig. 1).
Such improvements may be partly due to some patients
receiving more optimal medical treatment than they did
previously, but improvement in both treatment groups may be
partly due to regression to the mean. That is, patients tend to
enter a trial when their disease has deteriorated, and one may
anticipate some average improvement unrelated to the actual
treatment received.
Advances in treatment. Recently, medical and interven-
tional treatments for CAD have undergone important
advances. Compared with RITA-2 patients, one would now
expect patients to receive more extensive use of glycoprotein
IIb/IIIa receptor blockers, coronary stents during percuta-
neous coronary interventions and hydroxymethyl glutaryl
coenzyme A reductase inhibitors in the long term. The
quality-of-life impact of these advances is not documented,
but we suspect that the overall relative merits of continued
medical treatment versus immediate percutaneous coronary
interventions would not be substantially altered.
Other quality-of-life measures. With respect to other
quality-of-life instruments, the Nottingham Health Profile
seems less able to demonstrate treatment differences in
angina (7). The Seattle Angina Questionnaire (a more
disease-specific instrument) and the Euroqol instrument
(producing a single index as a utility measure for evaluating
cost-effectiveness) have both been added to the SF-36 in the
ongoing RITA-3 trial for patients with unstable angina or
non–Q wave MI, which compares an initially conservative
treatment strategy (optimal medical) with an initially inter-
ventional treatment strategy (early coronary arteriography
followed by appropriate myocardial revascularization).
Conclusions. In reaching an overall conclusion regarding
PTCA versus continued medical treatment, the quality-of-
life benefits of PTCA perceived by the patients themselves
add weight to the previously reported improvements in
angina, breathlessness and exercise tolerance. However,
there is no evidence, to date, of a prognostic survival benefit
after PTCA, and we have previously demonstrated a small
but nonnegligible procedure-related risk of nonfatal MI.
Hence, when managing the individual patient with angina,
clinicians must balance these benefits and risk in deciding
when to recommend PTCA.
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